Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
AssigneesAstellas US LLC, The Regents of the University of Michigan
InventorsBarbara P. Wallner, Kevin D. Cooper
Life of this patent
Estimating the term…
Abstract
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in mammals, including humans. Such conditions include psoriasis, UV damage, e.g., photoaging, atopic dermatitis, cutaneous T cell lymphoma such as mycosis fungoides, allergic and irritant contact dermatitis, lichen planus, alopecia areata, pyoderma gangrenosum, vitiligo, ocular cicatricial pemphigoid, and urticaria.
Claims68
A method of preventing or treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis, comprising the step of administering to a mammal a first agent that binds to LFA-3 or CD2 selected from the group consisting of an LFA-3 polypeptide, a CD2 polypeptide, an anti-CD2 antibody homolog, and an anti-LFA-3 antibody homolog, in combination with a therapeutic or prophylactic second agent, wherein the second agent is selected from the group consisting of:
- cyclosporin A, prednisone, FK506, methotrexate, steroids, retinoids, and nitrogen mustard.
Dependencies are inferred from the claim text.